EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types

Irina Robinson, Maximilian Johannes Hochmair iD, Manuela Schmidinger, Gudrun Absenger, Martin Pichler iD, Van Anh Nguyen iD, Erika Richtig iD, Barbara Margaretha Rainer, Leyla Ay, Christian Jansen, Cátia Pacífico iD, Alexander Knabl und 3 weitere

Cancers · 21.06.2023 · 15 (13) · 3268

DOI: 10.3390/cancers15133268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 21.06.2023. Verfasst von Irina Robinson und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biome Diagnostics GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The intestinal microbiome is by now an undebatable key player in the clinical outcome of ICI therapies. However, no microbiome profiling method to aid therapy decision is yet validated. We conducted a multi-centric study in patients with stage III/IV melanoma, NSCLC, or RCC receiving ICI treatment. The stool microbiome profile of 63 patients was analyzed with BiomeOne®, a microbiome-based algorithm that anticipates whether a patient will achieve clinical benefit with ICIs prior to therapy initiation. Classification of patient samples as Rs and NRs was achieved with a sensitivity of 81% and a specificity of 50% in this validation cohort. An ICI-favorable response was characterized by an intestinal microbiome rich in bacteria such as Oscillospira sp., Clostridia UCG-014, Lachnospiraceae UCG-010 sp., Prevotella copri, and a decrease in Sutterella sp., Lactobacillales, and Streptococcus sp. Patients who developed immune-related adverse events (irAEs) had an overall increased microbial diversity and richness, and a stool microbiome depleted in Agathobacter. When compared with the programmed death-ligand 1 (PD-L1) expression test in the subcohort of NSCLC patients (n = 38), BiomeOne® exhibited a numerically higher sensitivity (78.6%) in identifying responders when compared with the PD-L1 test (67.9%). This study provides an evaluation of BiomeOne®, the first microbiome-based test for prediction of ICI response, to achieve market authorization. Validation with further indications and expansion to other microbiome-based interventions will be essential to bring microbiome-based diagnostics into standard clinical practice.

Schlagwörter

Stichwörter der Autor:innen

PD-L1gut microbiomeimmunotherapymicrobiome profilingnext generation sequencing

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna Healthcare Group, 1210 Vienna, Austria.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
  • Department of Internal Medicine, Division of Oncology, Medical University of Graz, 8036 Graz, Austria.
  • Department of Dermatology, Medical University Innsbruck, 6020 Innsbruck, Austria.
  • Department of Dermatology, Medical University of Graz, 8036 Graz, Austria.
  • Biome Diagnostics GmbH, 1200 Vienna, Austria.

ORCID-Profile: Maximilian Johannes Hochmair, Martin Pichler, Van Anh Nguyen, Erika Richtig, Cátia Pacífico, Nikolaus Gasche

Förderung

  • Biome Diagnostics GmbH

Zitieren

APA

Robinson, I., Hochmair, M. J., Schmidinger, M., Absenger, G., Pichler, M., Nguyen, V. A., Richtig, E., Rainer, B. M., Ay, L., Jansen, C., Pacífico, C., Knabl, A., Sladek, B., Gasche, N., & Valipour, A. (2023). Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types. Cancers, 15(13), 3268. https://doi.org/10.3390/cancers15133268

Vancouver

Robinson I, Hochmair MJ, Schmidinger M, Absenger G, Pichler M, Nguyen VA, et al. Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types. Cancers. 2023;15(13):3268. doi:10.3390/cancers15133268

BibTeX
@article{Robinson2023,
  author = {Robinson, Irina and Hochmair, Maximilian Johannes and Schmidinger, Manuela and Absenger, Gudrun and Pichler, Martin and Nguyen, Van Anh and Richtig, Erika and Rainer, Barbara Margaretha and Ay, Leyla and Jansen, Christian and Pacífico, Cátia and Knabl, Alexander and Sladek, Barbara and Gasche, Nikolaus and Valipour, Arschang},
  title = {Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {13},
  pages = {3268},
  doi = {10.3390/cancers15133268}
}
Kostenlos starten →